1 citations,
March 2012 in “Journal of the American Academy of Dermatology” Botulinum toxin A injections may help treat difficult cases of total hair loss.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
June 2024 in “Skin Research and Technology” hsa-miR-193a-5p may help diagnose and treat alopecia areata.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
October 2023 in “The Cochrane library” The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
October 2023 in “Skin health and disease” Alopecia areata costs individuals about 3% of their income, with women, Asians, those with lower income, and more severe symptoms spending more.
August 2023 in “Medical Hypotheses” Metformin, usually used for diabetes, can also help treat hair loss from alopecia areata due to its ability to reduce inflammation and stimulate new hair growth.
July 2023 in “Clinical dermatology review” Intralesional triamcinolone acetonide is better than PRP for treating scalp alopecia areata, leading to faster and more complete hair regrowth.
June 2023 in “Journal of cosmetic dermatology” Both DPCP alone and with PRP are effective and safe for treating severe alopecia areata.
May 2023 in “Advances in medicine” Alopecia areata significantly impacts patients' mental health and quality of life.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
March 2023 in “Photodiagnosis and Photodynamic Therapy” Low vitamin D levels are linked to severe and active alopecia areata.
Microneedling with Triamcinolone acetonide is an effective, less invasive, and safe alternative to direct injections for treating alopecia areata.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
August 2022 in “Brain and Development” A nine-year-old girl with muscle weakness and total hair loss improved with specific treatments.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
March 2021 in “Annals of palliative medicine” Plum-blossom needling with conventional treatments improves hair regrowth in alopecia areata.
July 2019 in “International journal of dermatology, venereology and leprosy sciences” Oral cyclosporine works better than betamethasone minipulse therapy for treating Alopecia Areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
717 citations,
June 2010 in “Nature” Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.
143 citations,
January 2007 in “The American Journal of Human Genetics” Certain genes on chromosomes 6, 10, 16, and 18 may increase the risk of alopecia areata.
143 citations,
January 2004 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.
138 citations,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
106 citations,
January 2013 in “Clinical and Developmental Immunology” Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.
75 citations,
October 2012 in “Journal of Investigative Dermatology” Alopecia areata can be triggered by specific immune cells without genetic or environmental factors.
69 citations,
February 2008 in “The American journal of pathology” Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.